|
|||||
|
|
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis |
|
| Authors: | Niklas Bergvall Raquel Lahoz Tracy Reynolds Jonathan R Korn |
| Institution: | 1. Novartis Pharma AG BaselSwitzerland;2. IMS Health Waltham, MAUSA |
| Abstract: | |
| Keywords: | Administrative claims Effectiveness Fingolimod Healthcare resource Multiple sclerosis Natalizumab Relapses |